EVOLUS, INC. Deferred Revenue Recognized
EVOLUS, INC. (EOLS) reported Deferred Revenue Recognized of $9.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-05
- EVOLUS, INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $8.63M, a 36.61% decline year-over-year.
- EVOLUS, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $13.61M, a 47.93% increase year-over-year.
- EVOLUS, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $9.20M, a 20.87% increase year-over-year.
- EVOLUS, INC. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $7.61M, a 4.96% increase year-over-year.
- EVOLUS, INC. contract with customer, liability, revenue recognized for fiscal 2025 was $14.29M, a 39.85% increase from fiscal 2024.
- EVOLUS, INC. contract with customer, liability, revenue recognized for fiscal 2024 was $10.22M, a 29.89% increase from fiscal 2023.
- EVOLUS, INC. contract with customer, liability, revenue recognized for fiscal 2023 was $7.87M, a 3.99% increase from fiscal 2022.
- EVOLUS, INC. contract with customer, liability, revenue recognized for fiscal 2022 was $7.57M, a 170.02% increase from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.94M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $8.63M 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $14.29M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $14.22M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $13.83M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $13.61M 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | $10.22M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $10.08M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $9.77M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $9.20M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $7.87M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $7.75M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $7.69M 10-Q · filed 2024-07-31 | |||
| 2023-03-31 | $7.61M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $7.57M 10-K · filed 2025-03-04 | |||
| 2022-09-30 | $7.57M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $7.57M 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | $7.25M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $2.80M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $2.80M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $2.80M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | $1.51M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |